

Supplementary Table 1: Characteristics of solid organ transplant recipients with and without a 4 weeks follow-up after 2 doses mRNA-based vaccination.

| | SOT recipients with 4 weeks anti-SARS-CoV2 antibodies monitoring post-vaccination (N=393) | SOT recipients without 4 weeks anti-SARS-CoV2 antibodies monitoring post-vaccination (N=631) |
|---|---|--|
| Sex ratio (M/F) | 1.8 (251/142) | 1.6 (390/241) |
| Age (years, mean \pm SEM) | 59 \pm 1 | 58 \pm 1 |
| Type of organ transplant, n (%) | | |
| - Kidney | 288 (73) | 474 (75) |
| - Liver | 65 (17) | 104 (16) |
| - Thoracic organs | 35 (9) | 47 (7) |
| - Pancreas | 5 (1) | 6 (1) |
| History of rejection in the year preceding vaccination, n (%) | 5 (1) | 12 (2) |
| Time between vaccine and transplantation (months, mean \pm SEM) | 110 \pm 5 | 124 \pm 4 |
| No induction therapy, n (%) | 142 (36) | 234 (37) |
| Induction therapy, n (%) | 251 (64) | 397 (63) |
| - Anti-IL2 receptor | 144 (57) | 228 (57) |
| - Thymoglobulin | 104 (41) | 164 (41) |
| - Others | 3 (1) | 5 (1) |
| Type of immunosuppressive regimen, n (%) | | |
| - Anti-calcineurins | 331 (84) | 555 (88) |
| o Tacrolimus | 304 (92) | 511 (92) |
| o Ciclosporin A | 27 (8) | 44 (8) |
| - Antimetabolite | 277 (70) | 436 (69) |
| o Mycophenolic acid | 270 (97) | 427 (98) |
| o Azathioprine | 7 (3) | 9 (2) |
| - mTOR inhibitors | 101 (26) | 159 (25) |
| - Steroids | 307 (78) | 501 (79) |
| - Belatacept | 41 (10) | 37 (6) |

Abbreviations: SOT, solid organ transplant; IL2, interleukin 2; mTOR, mammalian target of rapamycin.

Supplementary Table 2: Clinical and biological characteristics of solid organ transplant recipients according to immunosuppressive regimen.

| | Immunosuppressive regimen | | |
|---|--|---|----------------------|
| | Tacrolimus + mycophenolic acid (N=210) | Tacrolimus + mTOR inhibitors (N=66) | Belatacept (N=41) |
| Sex ratio (M/F) | 1.6 (130/80) | 2 (44/22) | 3.6 (32/9) |
| Age (years, mean \pm SEM) | 58 \pm 1 | 56 \pm 2 | 63 \pm 2 |
| Type of organ transplant, n (%) | | | |
| - Kidney | 144 (69) | 53 (80) | 37 (90) |
| - Liver | 39 (19) | 3 (5) | - |
| - Thoracic organs | 23 (11) | 9 (14) | 4 (10) |
| - Pancreas | 4 (2) | 1 (2) | - |
| History of rejection in the year preceding vaccination, n (%) | 3 (1) | 1 (2) | 2 (5) |
| Time between vaccine and transplantation (months, mean \pm SEM) | 102 \pm 6 | 55 \pm 6 | 88 \pm 12 |
| No induction therapy, n (%) | 73 (35) | 24 (36) | 18 (44) |
| Induction therapy, n (%) | 137 (65) | 42 (64) | 23 (56) |
| - Anti-IL2 receptor | 78 (57) | 19 (45) | 17 (74) |
| - Thymoglobulin | 56 (41) | 23 (55) | 6 (26) |
| - Others | 3 (2) | - | - |
| Neutrophils count (/mm ³ , mean \pm SEM) | 5192 \pm 143 | 5007 \pm 244 | 5840 \pm 532 |
| Lymphocytes count (/mm ³ , mean \pm SEM) | 1766 \pm 99 | 1472 \pm 84 | 1520 \pm 141 |
| CD4+ T-cells count (/mm ³ , mean \pm SEM) | 502 \pm 34 | 400 \pm 37 | 431 \pm 51 |
| CD8+ T-cells count (/mm ³ , mean \pm SEM) | 442 \pm 42 | 360 \pm 35 | 496 \pm 72 |
| CD19+ cells count (/mm ³ , mean \pm SEM) | 104 \pm 12 | 72 \pm 12 | 106 \pm 35 |
| NK cells count (/mm ³ , mean \pm SEM) | 214 \pm 15 | 247 \pm 23 | 271 \pm 39 |
| eGFR (mL/min/1.73m ²) at baseline | | | |
| - Kidney transplant eGFR | 57 \pm 2 | 52 \pm 3 | 48 \pm 5 |
| - Non-kidney transplant eGFR | 61 \pm 3 | 58 \pm 7 | 62 \pm 16 |
| Anti-SARS-CoV2 antibodies positivity, % (n) | 27 (56/210) | 47 (31/66) | 15 (6/41) |

Abbreviations: IL2, interleukin 2; mTOR, mammalian target of rapamycin; NK, natural killer; eGFR, estimated Glomerular Filtration Rate (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation); COVID, coronavirus disease.